Kodiak's Zenkuda and tabirafusp-ted hit primary endpoints in Phase 3 DAYBREAK trial
Kodiak Sciences said both retinal drugs met their primary endpoints in the wAMD study, with plans to file a BLA for Zenkuda in the fourth quarter of 2026.
SEC filing
Latest
3 stories
Monday, September 28
Thursday, August 13
Kodiak reports Q2 2026 results, confirms three Phase 3 readouts by year-end
Kodiak said it remains on track for September DAYBREAK and December PEAK topline data, while cash fell to $125.9 million.
SEC filing